Be Biopharma has raised $92 million to support the first-in-human Phase 1/2 trial of BE-101, which is made to lower bleeding ...

Columnist Jennifer Lynne interviews Debbie Murray, a New Yorker whose hemophilia B diagnosis didn't occur until she was almost 51.

Now that his adult sons are managing their own hemophilia care, columnist Joe MacDonald is able to consider moving for a job.

Prophylactic, or preventive, treatment with factor VIII (FVIII) replacement therapy for four years reduced annual bleeding rates by 91% for people with severe hemophilia A, a study from Taiwan ...

When I tell people I’m a woman with hemophilia, I’m often met with the same response: “Well, that is really unusual. It’s rare for women to have hemophilia!” This ubiquitous misconception is the bane ...

Observing her husband, columnist Alliah Czarielle sees that getting older is a great equalizer, as more in their community have health woes.

Two hemophilia patients in the U.S. who struggled for years with bleeds have been given Hemgenix, the first gene therapy ...

Columnist Jennifer Lynne reflects on her most-read columns from last year and why those stories resonated with the hemophilia community.

Two new patients in the U.S. have received Hemgenix (etranacogene dezaparvovec), the first gene therapy to be approved for hemophilia B, per new reports. The therapy was first administered last year ...